Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115349 · ClinicalTrials.gov registry record · Phase 2
Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases
A Phase 2 study, sponsored by Carelon Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00115349 is a Phase 2 study that was terminated before completion, run by Carelon Research. The registered enrollment target is 20 participants.
The verdict
NCT00115349, a Phase 2 study, was terminated before completion, sponsored by Carelon Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether left ventricular function improves more rapidly with deferoxamine (DFO) and deferiprone (L1) combination therapy than with DFO monotherapy in patients with thalassemia and decreased ejection fractions. Secondary aims include evaluating changes in myocardial iron burden using T2\* and estimating the relative incidence and severity of chelator-induced toxicity.
Interventions
- DRUG Deferoxamine
- DRUG Deferiprone (L1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00115349
The ClinicalTrials.gov registry entry for NCT00115349 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carelon Research, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Deferoxamine is the first listed.
NCT00115349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00115349 about?
NCT00115349 is a clinical study titled "Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases". The purpose of this study is to determine whether left ventricular function improves more rapidly with deferoxamine (DFO) and deferiprone (L1) combination therapy than with DFO monotherapy in patients with thalassemia and decreased ejection fractions. Secondary aims include evaluating changes in myo...
What is the current status of trial NCT00115349?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-06. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00115349?
The interventions under investigation include: Deferoxamine (DRUG), Deferiprone (L1) (DRUG).
Who is sponsoring clinical trial NCT00115349?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.